

Radiation Oncology
P.O. Box 4587
500 W. Broadway
Missoula, MT 59807
p: 406.329.5655
f: 406.329.5675

RECEIVED
JAN 25 2016

DNMS



January 15, 2016

Nuclear Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region IV
1600 E. Lamar Boulevard
Arlington, TX 76011-4511

Re: Addition of Authorized Users for NRC License # 25-16773-02

Dear Sir/Madam;

We respectfully provide notification, pursuant to 10 CFR 35.14(a) of the addition of (3) authorized users. The individuals that have been accepted for authorized user status by Saint Patrick Hospital are as follows:

<u>Authorized Users</u>	<u>Material and Use</u>
Leslie A. Russell, M.D.	35.100; 35.200, 35.300, 31.11
Suzanne L. Shaw, M.D.	35.100; 35.200, 35.300, 31.11

In support of this notification, please note that these individuals are named as Authorized Users on USNRC Materials License # 25-27721-01 Amendment No. 15 for these materials and use. A copy of that document is enclosed.

<u>Authorized Users</u>	<u>Material and Use</u>
Kyle L. Dale, M.D.	35.100; 35.200, oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

In support of this notification, please note that this individual is named as an Authorized User on USNRC Materials License # 25-18361-01 Amendment No. 29 for these materials and use. A copy of that document is enclosed.

Thank you for your attention to this matter. If there are any questions or additional documentation is required please do not hesitate to contact me at (406) 327-1696.

Respectfully,

Patrick Martin, M.S.
Radiation Safety Officer
Saint Patrick Hospital
Missoula, Montana

PUBLIC
 Immediate Release
 Normal Release

NON-PUBLIC
 A.3 Sensitive-Security Related
 A.7 Sensitive Internal
 Other: _____

Reviewer: RAZ Date: 2-3-16

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Community Medical Center, Inc.</p> <p>2. 2827 Fort Missoula Road Missoula, Montana 59804</p>	<p>In accordance with application dated April 3, 2014</p> <p>3. License number 25-18361-01 is renewed in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2023</p> <hr/> <p>5. Docket No. 030-14921 Reference No. 25-29220-01 (030-37118)</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct materials permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Repackage Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 500 millicuries</p> <p>D. 50 millicuries</p>
--	--	--

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any use permitted by 10 CFR 35.300.
 - D. In vitro studies.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facility located at 2827 Fort Missoula Road, Missoula, Montana.
- B. Licensed material permitted by 10 CFR 35.200 (except gases), may be used for imaging and localization studies at temporary job sites of the licensee's anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
25-18361-01

Docket or Reference Number
030-14921 Reference No. 25-29220-01 (030-37118)

Amendment No. 29

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should contact the federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

11. The Radiation Safety Officer for this license is Christopher Fitz.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the material and medical uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Newton B. Coutinho, M.D.	35.200
Kyle L. Dale, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Joel A. Brake, M.D.	35.100; 35.200
Anthony R. D'Amico, M.D.	35.100; 35.200
Adam J. Benson, M.D.	35.100; 35.200; 35.300
Wayne L. Davis, M.D.	35.100; 35.200; 35.300; 31.11
Sarsfield Patrick Dougherty, M.D.	35.100; 35.200; 35.300; 31.11
Paul H. Eikens, M.D.	35.100; 35.200; 35.300; 31.11
Mark W. Elliott, M.D.	35.100; 35.200; 35.300; 31.11
Daniel M. Fruechte, M.D.	35.100; 35.200; 35.300; 31.11
James E. McKay, Jr., M.D.	35.100; 35.200; 35.300; 31.11
Michael A. Stewart, M.D.	35.100; 35.200; 35.300; 31.11
Michael R. Tryhus, M.D.	35.100; 35.200; 35.300; 31.11
Roy W. "Chip" Zimmer, III, M.D.	35.100; 35.200; 35.300; 31.11
David Bauer, M.D.	35.100; 35.200; oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
25-18361-01Docket or Reference Number
030-14921 Reference No. 25-29220-01 (030-37118)

Amendment No. 29

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 18, 2013

(ML13127A437)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: June 27, 2014

By:

Michelle M. Hammond, M.Sc., Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4511

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. CMSC, LLC d/b/a Great Falls Clinic Medical Center</p> <p>2. 3000 15th Avenue South Great Falls, Montana 59405</p>	<p>In accordance with letter dated September 27, 2015</p> <p>3. License number 25-27721-01 is amended in its entirety to read as follows:</p>
	<p>4. Expiration date August 31, 2022</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct materials permitted in 10 CFR 31.11</p>	<p>5. Docket No. 030-35944 Reference No.</p> <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackage Kits</p> <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 900 millicuries</p> <p>D. 100 millicuries</p>
<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any use permitted by 10 CFR 35.300.</p> <p>D. <i>In vitro</i> studies.</p>	

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at:
- A. Great Falls Clinic, Specialty Center, 3000 15th Avenue South, Great Falls, Montana,
 B. Great Falls Clinic Medical Center, 3010 15th Avenue South, Great Falls, Montana,
 C. Great Falls Clinic, Surgery Center, 1509 29th Street South, Great Falls, Montana, and
 D. Great Falls Clinic Medical Center, 1411 9th Street South, Great Falls, Montana.
11. The Radiation Safety Officer for this license is Kari L. Cann.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
25-27721-01


Docket or Reference Number
030-35944

Amendment No. 15

12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the material and medical uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
James T. Harris, M.D.	35.100; 35.200; 35.300; 31.11
Jeffrey R. Kessler, M.D.	35.100; 35.200; 35.300; 31.11
George Ro, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
Leslie A. Russell, M.D.	35.100; 35.200; 35.300; 31.11
Suzanne L. Shaw, M.D.	35.100; 35.200; 35.300; 31.11
Michael J. Walters, M.D.	35.100; 35.200; 35.300
Tyler L. Will, M.D.	35.100; 35.200; 35.300; 31.11
Andrew Baugh, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131
James Daniel, M.D.	35.100; 35.200; Oral administration of sodium iodide I-131


13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
25-27721-01Docket or Reference Number
030-35944

Amendment No. 15

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 7, 2012 (ML12047A331)
 - B. Application dated July 27, 2012 (ML12219A297)
 - C. Facsimile dated May 28, 2013 (ML13149A180)
 - D. Letters dated September 27, 2013 (ML13277A735)
 - E. Letter dated August 1, 2015 (ML15275A046)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: December 22, 2015By: _____
Jacqueline D. Cook, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4511

RECEIVED
JAN 25 2016

DNMS

MONTANA CANCER CENTER
AT PROVIDENCE ST PATRICK HOSPITAL
RADIATION ONCOLOGY DEPARTMENT
500 W. BROADWAY
MISSOULA, MT 59802

Hasler
01/16/2016
TELESTATE \$001
DATE

Nuclear Materials Licensing Section
U.S. Nuclear Regulatory Commission, Region IV
1600 E. Lamar Boulevard
Arlington TX 76011-4311

968889

RECEIVED JAN 22 2015



DATE
01/25/2016

NAME AND ADDRESS OF APPLICANT AND/OR LICENSEE Mr. Patrick H. Martin, M.S. Radiation Safety Officer Saint Patrick Hospital and Health Sciences Center P.O. Box 4587 Missoula, MT 59806	LICENSE NUMBER 25-16773-02
	MAIL CONTROL NUMBER 589996
	LICENSING AND/OR TECHNICAL REVIEWER CH

This is to acknowledge the receipt of your:

LETTER and/or APPLICATION DATED: 01/15/2016

The initial processing, which included an administrative review, has been performed.

AMENDMENT TERMINATION NEW LICENSE RENEWAL

- There were no administrative omissions identified during our initial review.
- This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.
- Your application for a new NRC license did not include your taxpayer identification number. Please fill out NRC Form 531, located at the following link:

<http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf>

Send the completed NRC Form 531, by facsimile, to the following number: (301) 415-5387

A copy of your action has been emailed to our License Fee and Accounts Receivable Branch, in our Headquarters office in Rockville, MD. You will be contacted separately if there is a fee issue involved.

Your application has been assigned the above listed **MAIL CONTROL NUMBER**. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:

Region IV
U. S. Nuclear Regulatory Commission
DNMS/NMSB - B
1600 E. Lamar Boulevard
Arlington, TX 76011-4511
(817) 200-1140

✓ 1/25/16

BETWEEN:

Accounts Receivable/Payable
and
Regional Licensing Branches

[FOR ARPB USE]
INFORMATION FROM WBL

Program Code: 02230
Status Code: Pending Amendment
Fee Category: 3E 7C
Exp. Date: 07/31/2015
Fee Comments: CALIBRATE THEIR OWN
Decom Fin Assur Req: N

License Fee Worksheet - License Fee Transmittal

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: Saint Patrick Hospital and Health Sciences Center
Received Date: 01/25/2016
Docket Number: 3014734
Mail Control Number: 589996
License Number: 25-16773-02
Action Type: Amendment

2. FEE ATTACHED

Amount: _____

Check No.: _____

3. COMMENTS

Signed: _____

Carl P. Heie

Date: _____

1/25/16

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:

Amendment: _____

Renewal: _____

License: _____

3. OTHER _____

Signed: _____

Date: _____